FDA Approvals - Episode 5

FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

January 26, 2018

EP. 1: FDA Approval for Lutathera in Neuroendocrine Tumors

EP. 2: FDA Approval of Second Dosing Schedule of Nivolumab

EP. 3: FDA Approval of Frontline Nivolumab/Ipilimumab Combo in RCC

EP. 4: FDA Approval of Durvalumab for Stage III Unresectable NSCLC

Now Viewing

EP. 5: FDA Approval of Brentuximab Vedotin Plus AVD in Classical Hodgkin Lymphoma

EP. 6: FDA Approval of Frontline Osimertinib in Frontline EGFR-Mutant NSCLC

EP. 7: FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ Melanoma

EP. 8: FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

Hello and welcome to OncLive News Network, Breaking News. I'm Gina Columbus.

The FDA has granted an approval to brentuximab vedotin (Adcetris) in combination with adriamycin, vinblastine, and dacarbazine as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

The decision is based on findings from the phase III ECHELON-1 trial, in which brentuximab vedotin plus AVD compared with standard ABVD, known as AVD plus bleomycin, demonstrated superior progression-free survival.

In the study, the brentuximab vedotin regimen reduced the risk of progression, death, or initiation of new therapy by 23% versus ABVD. The 2-year modified PFS rate was 82.1% with brentuximab vedotin compared with 77.25% for standard chemotherapy.

The FDA granted a breakthrough therapy designation for brentuximab vedotin in combination with chemotherapy for frontline advanced classical Hodgkin lymphoma in October 2017.

For more breaking news, subscribe to email alerts from OncLive.com. Thank you for watching! I'm Gina Columbus.